Phaseline

Targets › KRT5

KRT5 (Keratin, type II cytoskeletal 5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Jan 2027.

Structural component of intermediate filaments in basal keratinocytes of stratified epithelia. Forms heteropolymers with type I partners including KRT14 and KRT15, contributing to the formation of the keratin intermediate filament network that provides mechanical stability and resilience to the basal layer of the epidermis. (UniProt, P13647)

Open in Phaseline: the race on KRT5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioMendicsTolaSure Topical Gel
Topical agent targeting aggregated mutant keratin
KRT5Phase 2Epidermolysis Bullosa SimplexJan 2027

Conditions

Epidermolysis Bullosa Simplex (1)

Modalities

small molecule (1)

Companies

BioMendics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.